Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01522937 · ClinicalTrials.gov registry record · Phase 2
A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer
A Phase 2 study of Liver Cancer and Hepatocellular Cancer, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 94
- Enrollment target
- 1
- Study location
NCT01522937: Completed Phase 2 study of Liver Cancer and Hepatocellular Cancer, sponsored by University of Michigan Rogel Cancer Center.
NCT01522937 is a Phase 2 study of Liver Cancer and Hepatocellular Cancer that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 94 participants, below the 447-participant average among 78 other Liver Cancer trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01522937, a Phase 2 study of Liver Cancer and Hepatocellular Cancer, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 94 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase II trial to characterize the safety and efficacy of individualized stereotactic body radiation therapy (SRBT) for patients who have had previous liver treatment or who have primary hepatocellular carcinoma (HCC).
Primary Outcome
For this study, local control is defined as the lack of progressive local disease following CR (Complete Response) or PR (Partial Response), or lack of progressive local disease in patients with non-evaluable disease, who have no progressive elevation in serum tumor markers.
Conditions Studied
Interventions
- RADIATION individualized Stereotactic Body Radiation Therapy (SBRT)
Study Locations (1)
Michigan
- University of Michigan Comprehensive Cancer Center - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 94 participants |
| Start Date | 2009-10 |
| Est. Completion | 2015-11 |
| Phase | Phase 2 |
What the finished NCT01522937 record still lists
NCT01522937 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 94 participants, a relatively small participant target, below the 447-participant average among 78 other Liver Cancer trials with a reported enrollment target (79% lower).
The record links to 2 conditions, with Liver Cancer appearing as the primary indexed condition, and to 1 intervention - of which individualized Stereotactic Body Radiation Therapy (SBRT) is the first listed.
NCT01522937 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT01522937 about?
NCT01522937 is a clinical study titled "A Study of Individualized Stereotactic Body Radiation Therapy (SBRT) for Intrahepatic Cancer". This is a Phase II trial to characterize the safety and efficacy of individualized stereotactic body radiation therapy (SRBT) for patients who have had previous liver treatment or who have primary hepatocellular carcinoma (HCC).
What is the current status of trial NCT01522937?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 94 participants. The study started on 2009-10. Estimated completion is 2015-11.
What conditions does trial NCT01522937 study?
This clinical trial studies the following conditions: Liver Cancer, Hepatocellular Cancer.
What interventions are being tested in trial NCT01522937?
The interventions under investigation include: individualized Stereotactic Body Radiation Therapy (SBRT) (RADIATION).
Who is sponsoring clinical trial NCT01522937?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01522937 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01522937's enrollment target sits among peer trials
94 30th of 78 higher than 49 of 78 other Liver Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Liver Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
RECRUITING · Phase 2
-
Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma
RECRUITING · Phase 2
-
REGULUS: MRI-guided Adaptive SABR for Liver Cancers
RECRUITING · Phase 2
-
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
RECRUITING · Phase 2
-
Y-90 Treatment Response Using Transarterial Radioembolization
RECRUITING · Phase 2
-
Domvanalimab and Zimberelimab in Advanced Liver Cancers
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03747146 · 94 participants · NA
Enhanced Recovery After Surgery (ERAS) Total Knee Replacement (TKR) With a Transitional Pain Service
- NCT04061421 · 94 participants · Phase 1
Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
- NCT04205968 · 94 participants · Phase 2
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers
- NCT04464759 · 94 participants · Phase 1
A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia